Birch Hill Investment Advisors LLC Acquires 160,411 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Birch Hill Investment Advisors increased its Bristol Myers Squibb stake by 2,774.3%, acquiring 160,411 additional shares and bringing its holdings to 166,193 shares valued at approximately $10.37 million.
• Institutional investors own 76.41% of BMY, while analysts maintain a consensus “Moderate Buy” rating with an average price target of $64.88; recent targets range from $75 to $82.
• Bristol Myers Squibb reported stronger-than-expected quarterly results and declared a quarterly dividend of $0.63, representing a 4.2% annualized yield. Investors remain focused on the company’s roughly $43 billion debt load and upcoming patent expirations.

Birch Hill Investment Advisors LLC increased its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 2,774.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 166,193 shares of the biopharmaceutical company's stock after buying an additional 160,411 shares during the quarter. Birch Hill Investment Advisors LLC's holdings in Bristol Myers Squibb were worth $10,370,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in the company. Lazard Asset Management LLC boosted its stake in Bristol Myers Squibb by 23.7% during the first quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company's stock worth $116,693,000 after acquiring an additional 368,193 shares in the last quarter. Callan Family Office LLC acquired a new stake in Bristol Myers Squibb in the 2nd quarter valued at $3,575,000. BlackRock Inc. increased its stake in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. Saudi Central Bank raised its holdings in shares of Bristol Myers Squibb by 90.2% in the 2nd quarter. Saudi Central Bank now owns 142,922 shares of the biopharmaceutical company's stock worth $8,235,000 after acquiring an additional 67,780 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Bristol Myers Squibb in the 2nd quarter valued at about $1,901,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.05% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on BMY shares. Piper Sandler reissued an "overweight" rating and issued a $82.00 price target (up from $75.00) on shares of Bristol Myers Squibb in a research report on Wednesday, September 16th. Weiss Ratings raised Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, August 18th. Argus raised shares of Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 price target on the stock in a report on Wednesday, August 5th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $76.00 price objective on shares of Bristol Myers Squibb in a research report on Monday, October 12th. Finally, UBS Group cut shares of Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a report on Wednesday, August 5th. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $64.88.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Recent late-stage data support the company’s effort to replace revenue from aging medicines. Bristol Myers Squibb reported positive Phase 3 topline results for RYZ101 in gastroenteropancreatic neuroendocrine tumors and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. The breadth of the pipeline could strengthen long-term growth if the programs successfully reach the market. How Positive Phase 3 Results Will Impact Bristol Myers Squibb Stock Investors
• Positive Sentiment: Admilparant remains potentially viable as a pulmonary-fibrosis treatment despite mixed Phase 3 results, with UBS reportedly maintaining a constructive view. The lower dose met the primary endpoint, preserving some commercial potential. Bristol-Myers Squibb's Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
• Neutral Sentiment: BMY’s roughly 40% one-year rally has been supported by new medicines, revenue growth and higher earnings guidance. However, its low valuation—about 9.36 times forward earnings—suggests investors remain cautious about whether the new portfolio can justify additional upside. Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside?
• Negative Sentiment: The company’s approximately $43 billion debt load and looming patent cliff create concerns about future cash flow and dividend growth. Bristol Myers Squibb’s 4.2% yield and 17-year record of dividend increases may be attractive, but investors are questioning whether upcoming launches can offset declining legacy-drug revenue. Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $59.69 on Friday. The firm has a market capitalization of $121.94 billion, a price-to-earnings ratio of 13.15, a P/E/G ratio of 0.30 and a beta of 0.19. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The stock has a fifty day moving average of $63.55 and a 200 day moving average of $60.29. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.56 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.